INVESTOR RELATIONS

At the heart of True Dose is our patented blood sampling kit, designed to revolutionize Therapeutic Drug Monitoring (TDM). By combining precision with simplicity, our technology ensures patients can seamlessly collect blood samples from the comfort of their homes, without the need for temperature-controlled transport or complex logistics.

Our innovative approach incorporates a self-sealing cap with an internal standard, allowing for real-time stabilization of the blood sample. This unique feature maintains the accuracy and integrity of the sample during transport, ensuring lab-quality results without the usual challenges. In addition, the extended shelf life of our kit - lasting up to 14 days - provides flexibility in storage and distribution, further enhancing its practicality for both patients and healthcare providers.

The True Dose kit is designed for patient-centric care, enhancing convenience and ensuring greater adherence to treatment protocols, especially for chronic disease management and cancer therapies. At the same time, it streamlines the workflow for healthcare providers, reducing the logistical challenges and costs associated with conventional lab-based blood sampling.

In short, our technology represents a game-changer in the way therapeutic drug monitoring is performed, offering a cost-effective, efficient, and highly accurate solution for personalized dosing - ensuring that every patient receives the right dose, at the right time.

True Dose is uniquely positioned to capture significant market share across three rapidly expanding segments: Pharma/Biotech, Healthcare, and Research Groups. Each of these areas presents immense growth opportunities driven by the rising demand for better and more efficient health care.

• Pharma/Biotech: The biggest revenue potential for True Dose lies in Pharma and Biotech. Our TDM solution addresses a critical gap in clinical trials, where current drug dosing methods and the lack of infrastructure—such as research nurses and hospital beds—are often barriers to patient recruitment and retention. As Thomas Helleday mentions, “The True Dose kit offers a unique opportunity to measure pharmacokinetics in clinical trials without the need for a study nurse and hospital beds. This is the perfect solution.” By simplifying the sampling process and delivering precise data on drug exposure, True Dose empowers pharmaceutical companies to accelerate drug development, ensure patient safety, and reduce costs.

• Healthcare: Globally, over 23 million new cancer cases are diagnosed annually, and improper dosing remains a major issue—only 45% of patients receive the correct dose, with 38% underdosed and 17% overdosed, leading to relapses or severe side effects. Our technology optimizes treatment by providing on-demand drug concentration data, reducing hospital stays, enhancing patient outcomes, and lowering healthcare costs. While cancer is our initial focus, the need for precise dosing extends to all chronic diseases, where personalized treatment will have a transformative impact.

• Research Groups: While not the largest revenue driver, our collaborations with research institutions and academic groups are key to True Dose’s long-term strategy. These partnerships allow us to participate in cutting-edge research and stay at the forefront of technological innovations in personalized medicine. The relationships we build here will keep True Dose in a leading position as new breakthroughs emerge in the field.

True Dose has already demonstrated significant benefits through our performance and usability studies. These studies provide concrete evidence of the accuracy and reliability of our at-home blood sampling technology, which has shown results that align with traditional lab-based methods.

In our performance study, we successfully validated that our kit consistently delivers accurate drug concentration measurements, matching those obtained through traditional venous sampling. This proves that at-home therapeutic drug monitoring (TDM) can be as precise as hospital-based methods while offering unmatched convenience for the patient.

Moreover, our usability study confirms that patients find the True Dose kit easy to use, ensuring higher adherence to prescribed treatments. This is crucial, as increased adherence directly correlates with improved treatment outcomes—particularly for chronic conditions and cancer therapies where correct dosing is vital.

By reducing the need for clinic visits and lab-dependent procedures, True Dose empowers patients, enhances their quality of life, and provides healthcare providers with the data they need to make informed, personalized treatment decisions. These real-world results show our solution’s potential to transform how therapeutic drug monitoring is conducted—ensuring precise dosing, minimizing side effects, and optimizing treatment efficacy across the board.

True Dose has built a multi-faceted and scalable business model that taps into multiple revenue streams, ensuring both immediate impact and long-term growth.

• Pharma/Biotech:

  True Dose plays a critical role in the clinical trial ecosystem, providing pharmaceutical companies and clinical research organizations with a reliable, easy-to-use platform for monitoring drug concentrations with ease. Whether for new drug development or optimizing existing treatments, our technology streamlines the process, enhances data accuracy, and reduces patient dropout rates. This positions us as a valuable partner in the $100 billion clinical trial industry, accelerating drug development timelines for market access and reducing trial costs.

• Healthcare Providers & Insurance Companies:

  We generate revenue through direct sales to both private and public healthcare providers, as well as insurance companies. By reducing hospital visits, minimizing adverse effects, and improving patient outcomes, True Dose offers a cost-effective solution that enhances patient care and operational efficiency for healthcare systems. For insurance companies, this means fewer claims related to complications, hospital readmissions, and prolonged treatments—ultimately lowering overall healthcare costs and improving profitability.

• Data Analytics & Insights:

  As we continue to collect masked and de-identified data from thousands of patients using our platform, we unlock a unique revenue stream through data analytics. With access to a rich database of real-world drug concentration and patient outcomes, we can provide valuable insights to pharmaceutical companies, helping them optimize drug efficacy, understand patient responses, and enhance future drug formulations. Our data will offer pharma companies actionable intelligence on how their drugs perform in diverse patient populations, opening the door to strategic partnerships and further revenue opportunities.

• Research Groups:

  Although not expected to be as substantial a contributor to revenue as Pharma, Healthcare and Data, research groups represent a vital strategic segment. Collaborating with academic institutions and research groups positions True Dose at the forefront of innovation. These partnerships expand our network, foster breakthrough research, and ensure we remain ahead in technological advancements. The connections we build here will fuel future growth and keep us aligned with cutting-edge developments in personalized medicine.

True Dose’s robust, diversified business model is designed for scalability and sustained profitability, leveraging the growing demand for personalized medicine, clinical trial innovations, and real-world data. By addressing key pain points in both healthcare and drug development, we are positioned to lead in precision medicine while maximizing long-term growth.

Our leadership team is composed of industry experts with a wealth of experience in clinical research, medical technology development, and scaling innovative businesses.

• With decades of combined expertise in oncology, pharmacology, and technology, our founders have been at the forefront of personalized medicine long before it became a widespread initiative.

• One of our co-founders is a leading oncologist in Sweden, contributing groundbreaking research in breast cancer treatment and drug monitoring for over 20 years. Another is an R&D expert and chemist who has spent the last decade pioneering advancements in blood sampling technologies. Together, they have shaped a solution grounded in real-world research and patient-centric care.

• Our leadership also includes professionals with extensive experience in commercial strategy, regulatory affairs, and market expansion, ensuring that True Dose is not only clinically sound but also commercially viable.

With a proven track record in successfully navigating the complex healthcare landscape and driving product innovation, our team is uniquely positioned to lead True Dose in its mission to revolutionize therapeutic drug monitoring and drive the future of precision medicine forward.

True Dose has already secured over €1.2 million in funding, demonstrating strong investor confidence in our vision and technology. This backing has been instrumental in advancing our product development, conducting clinical studies, and scaling our operations to meet growing market demand. 

Our investors recognize the transformative potential of precision medicine and have supported us in building a sustainable and scalable business model. As we continue to grow, we are positioned for strategic partnerships and further investment rounds, propelling True Dose into the next phase of global expansion and market leadership in therapeutic drug monitoring.